Power-Laws and the Use of Pluripotent Stem Cell Lines

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Schuldt, Bernhard M ^a   Guhr, Anke ^b   Lenz, Michael ^a   Kobold, Sabine ^b   MacArthur, Ben D ^c,d   Schuppert, Andreas ^a   Löser, Peter ^b   Müller, Franz Josef ^e  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e Zentrum fur Integrative Psychiatrie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL CULTURE; CELL LINE; DESCRIPTIVE RESEARCH; EMBRYO; EMBRYONIC STEM CELL; GOVERNMENT REGULATION; HUMAN; HUMAN CELL; MEDICAL RESEARCH; PLURIPOTENT STEM CELL; POLICY;

BIOMEDICAL RESEARCH; CELL LINE; CLUSTER ANALYSIS; COMPUTER SIMULATION; EMBRYONIC STEM CELLS; HUMANS; PLURIPOTENT STEM CELLS; PUBLIC POLICY; REGENERATIVE MEDICINE; STEM CELL RESEARCH; UNITED STATES;

EID: 84871749362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052068     Document Type: Article

References (57)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-1147.
2. Guhr A, Kurtz A, Friedgen K, Loser P, (2006) Current state of human embryonic stem cell research: an overview of cell lines and their use in experimental work. Stem Cells 24: 2187-2191.
3. Scott CT, McCormick JB, Owen-Smith J, (2009) And then there were two: use of hESC lines. Nat Biotechnol 27: 696-697.
4. McCormick JB, Owen-Smith J, Scott CT, (2009) Distribution of human embryonic stem cell lines: who, when, and where. Cell Stem Cell 4: 107-110.
5. Löser P, Schirm J, Guhr A, Wobus AM, Kurtz A, (2010) Human embryonic stem cell lines and their use in international research. Stem Cells 28: 240-246.
6. Scott CT, McCormick JB, Derouen MC, Owen-Smith J, (2010) Federal policy and the use of pluripotent stem cells. Nat Methods 7: 866-867.
7. Schlaeger TM, Lensch MW, Taylor PL, (2007) Science aside: the trajectory of embryonic stem cell research in the USA. Drug Discov Today 12: 269-271.
8. Vogel G, (2001) Biomedical policy. Bush squeezes between the lines on stem cells. Science 293: 1242-1245.
9. Owen-Smith J, McCormick J, (2006) An international gap in human ES cell research. Nat Biotechnol 24: 391-392.
10. Levine AD, (2008) Identifying under- and overperforming countries in research related to human embryonic stem cells. Cell Stem Cell 2: 521-524.
11. Scott CT, McCormick JB, DeRouen MC, Owen-Smith J, (2011) Democracy derived? New trajectories in pluripotent stem cell research. Cell 145: 820-826.
12. Holden C, (2009) Obama executive order. For Congress and NIH, headaches ahead on stem cells. Science 323: 1552-1553.
13. Karmali RN, Jones NM, Levine AD, (2010) Tracking and assessing the rise of state-funded stem cell research. Nat Biotechnol 28: 1246-1248.
14. Scott CT, McCormick JB, Owen-Smith J, (2009) We must reverse the Bush legacy of stem-cell problems. Nature 460: 33.
15. Patel R, Lomax G, (2011) Use of hESC Lines by CIRM Grantees: The Value of Embryonic Stem Cell Research Oversight (ESCRO) Committees. J Stem Cell Res Ther 1: 107.
16. Levine AD, (2011) Policy uncertainty and the conduct of stem cell research. Cell Stem Cell 8: 132-135.
17. Levine AD, (2011) Access to human embryonic stem cell lines. Nat Biotechnol 29: 1079-1081.
18. Müller FJ, Goldmann J, Loser P, Loring JF, (2010) A call to standardize teratoma assays used to define human pluripotent cell lines. Cell Stem Cell 6: 412-414.
19. Price DDS, (1976) A general theory of bibliometric and other cumulative advantage processes. Journal of the American Society for Information Science 27: 292-306.
20. Simon HA, (1955) On a class of skew distribution functions. Biometrika 42: 425-440.
21. Morris SA (2005) Bipartite Yule Processes in Collections of Journal Papers. 10th International Conference of the International Society for Scientometrics and Informetrics Stockholm, Sweden.
22. Csardi G, Nepusz T (2006) The igraph software package for complex network research. InterJournal Complex Systems 1695.
23. Clauset AS, C. R.; Newman, M. E J, (2009) Power-Law Distributions in Empirical Data. SIAM Rev 51: 661-703.
24. Newman MEJ (2009) The first-mover advantage in scientific publication. Europhysics Letters 86: Art. Nr. 68001.
25. Gentleman R (2005) Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer Science+Business Media. xix, 473 p. p.
26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
27. Venables W, Ripley B (2002) Modern Applied Statistics with S. Fourth Edition: Springer. 495 p.
28. Barabasi AL, Albert R, (1999) Emergence of scaling in random networks. Science 286: 509-512.
29. Price DJ, (1965) Networks of Scientific Papers. Science 149: 510-515.
30. Aldhous P, (2005) Stem-cell research: after the gold rush. Nature 434: 694-696.
31. Miller G, (2010) Regenerative medicine. CIRM: the good, the bad, and the ugly. Science 330: 1742-1743.
32. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
33. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
34. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, et al. (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26: 101-106.
35. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
36. Vogel G, (2008) Breakthrough of the year. Reprogramming Cells. Science 322: 1766-1767.
37. Pera MF, (2011) Stem cells: The dark side of induced pluripotency. Nature 471: 46-47.
38. Luong MX, Auerbach J, Crook JM, Daheron L, Hei D, et al. (2011) A call for standardized naming and reporting of human ESC and iPSC lines. Cell Stem Cell 8: 357-359.
39. Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J, et al. (2004) Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 350: 1353-1356.
40. Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, et al. (2010) Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell 141: 872-883.
41. Stumpf MP, Porter MA, (2012) Mathematics. Critical truths about power laws. Science 335: 665-666.
42. Chung Y, Klimanskaya I, Becker S, Li T, Maserati M, et al. (2008) Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell 2: 113-117.
43. Fletcher JM, Ferrier PM, Gardner JO, Harkness L, Dhanjal S, et al. (2006) Variations in humanized and defined culture conditions supporting derivation of new human embryonic stem cell lines. Cloning Stem Cells 8: 319-334.
44. Zhang X, Stojkovic P, Przyborski S, Cooke M, Armstrong L, et al. (2006) Derivation of human embryonic stem cells from developing and arrested embryos. Stem Cells 24: 2669-2676.
45. Peura TT, Bosman A, Stojanov T, (2007) Derivation of human embryonic stem cell lines. Theriogenology 67: 32-42.
46. Lerou PH, Yabuuchi A, Huo H, Takeuchi A, Shea J, et al. (2008) Human embryonic stem cell derivation from poor-quality embryos. Nat Biotechnol 26: 212-214.
47. Mateizel I, De Temmerman N, Ullmann U, Cauffman G, Sermon K, et al. (2006) Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 21: 503-511.
48. Crook JM, Peura TT, Kravets L, Bosman AG, Buzzard JJ, et al. (2007) The Generation of Six Clinical-Grade Human Embryonic Stem Cell Lines. Cell Stem Cell 1: 490-494.
49. Lin G, Xie Y, Ouyang Q, Qian X, Xie P, et al. (2009) HLA-matching potential of an established human embryonic stem cell bank in China. Cell Stem Cell 5: 461-465.
50. Simon C, Escobedo C, Valbuena D, Genbacev O, Galan A, et al. (2005) First derivation in Spain of human embryonic stem cell lines: use of long-term cryopreserved embryos and animal-free conditions. Fertil Steril 83: 246-249.
51. Fraga AM, Sukoyan M, Rajan P, Braga DP, Iaconelli A Jr, et al. (2011) Establishment of a Brazilian line of human embryonic stem cells in defined medium: implications for cell therapy in an ethnically diverse population. Cell Transplant 20: 431-440.
52. O'Rourke PP, Abelman M, Heffernan KG, (2008) Centralized banks for human embryonic stem cells: a worthwhile challenge. Cell Stem Cell 2: 307-312.
53. Isasi RM, Knoppers BM, (2009) Governing stem cell banks and registries: emerging issues. Stem Cell Res 3: 96-105.
54. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, et al. (2007) Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 25: 803-816.
55. (2009) Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy. MENLO PARK, Calif.: Geron Corporation.
56. Martin MJ, Muotri A, Gage F, Varki A, (2005) Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 11: 228-232.
57. Russo E, (2005) Follow the money-the politics of embryonic stem cell research. PLoS Biol 3: e234.